Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era

Cori Campbell; Monique Andersson; M. Azim Ansari; Olivia Moswela; Siraj A Misbah; Paul Klenerman; Philippa C Matthews.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21254128

Documentos relacionados

  1. Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era.
  2. [Efficacy of Novafon Local Vibration Voice Therapy and Water Resistance Therapy: a meta-analysis].
  3. [Online schema therapy: a cross-sectional survey among Dutch therapists].
  4. [Intrathecal baclofen therapy: a 30-year experience].
  5. [Health service aspects of electroconvulsive therapy: analysis of external referrals to a university medical center].
  6. [Hepatitis C therapy: a problem almost solved].
  7. [Osteoporosis in androgen deprivation therapy: finding the balance between social and individual interests].
  8. [Healthcare Research into Anti-VEGF Therapy: Selection and Methodological Precautions].
  9. [Spontaneous retroperitoneal and rectus sheath hematomas and their interventional therapy: a review].
  10. [Goal-directed hemodynamic therapy: Concepts, indications and risks].